DBV Technologies (DBVT) Fundamentals 2026 — Revenue Analysis | SniperIQ
DBV Technologies (DBVT) is a FR-listed Healthcare company in Biotechnology with a market capitalization of
DBV Technologies (DBVT) has a market capitalization of approximately
DBV Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
DBV Technologies runs a net profit margin of -18636.8%, a gross margin of -1303.2%, and an operating margin of -19112.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
DBV Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
DBV Technologies carries a debt-to-equity ratio of 0.03x and a current ratio of 4.76x, with a market beta of -0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For DBV Technologies (DBVT) the key facts are: market cap
Get DBV Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.